Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study
Epilepsia ( IF 5.6 ) Pub Date : 2021-07-13 , DOI: 10.1111/epi.17007 Jacqueline A French 1 , Steve S Chung 2 , Gregory L Krauss 3 , Sang Kun Lee 4 , Maciej Maciejowski 5 , William E Rosenfeld 6 , Michael R Sperling 7 , Marc Kamin 8
Epilepsia ( IF 5.6 ) Pub Date : 2021-07-13 , DOI: 10.1111/epi.17007 Jacqueline A French 1 , Steve S Chung 2 , Gregory L Krauss 3 , Sang Kun Lee 4 , Maciej Maciejowski 5 , William E Rosenfeld 6 , Michael R Sperling 7 , Marc Kamin 8
Affiliation
This study was undertaken to examine long-term (up to 7.8 years) retention rate, safety, and tolerability of the antiseizure medication (ASM) cenobamate as adjunctive treatment in the open-label extension (OLE) of study YKP3089C013 (C013; ClinicalTrials.gov: NCT01397968).
中文翻译：
未控制的局灶性癫痫患者中辅助用药的长期安全性：一项随机临床研究的开放标签扩展
本研究旨在检验 YKP3089C013 (C013; ClinicalTrials.政府：NCT01397968）。
更新日期：2021-08-29
中文翻译：
未控制的局灶性癫痫患者中辅助用药的长期安全性：一项随机临床研究的开放标签扩展
本研究旨在检验 YKP3089C013 (C013; ClinicalTrials.政府：NCT01397968）。
京公网安备 11010802027423号